ASCO 2024 EGFR Mutated NSCLC

CME

Expert Perspectives on the Evolving Treatment of EGFR-Mutated Advanced and Metastatic NSCLC

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Released: June 12, 2024

Expiration: June 11, 2025

Nicolas Girard
Nicolas Girard, MD, PhD
Natasha Leighl
Natasha Leighl, MD, MMSc, FRCPC, FASCO
Karen Reckamp
Karen Reckamp, MD, MS

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Presurvey 1: Which of the following treatment options would be a preferred first-line therapy for a patient with EGFR G719X mutated NSCLC?

2.

Presurvey 2: Your patient with advanced EGFR-mutated, PD-L1 >50% NSCLC had PD on third-generation TKI and platinum-based CT. He has a history of previously treated, currently asymptomatic, brain metastases. How would you counsel this patient to help determine his eligibility for an ongoing clinical trial of novel targeted therapies? 

3.

Patient Case 4: 63-Year-Old Psychiatrist With History of Cardiovascular Disease, Current Smoker



  • 1L treatment: Carboplatin/pemetrexed with bevacizumab

    • Palliative RT to L2 and L5 vertebrae






  • After 4 cycles: PD on the primary lung tumour



Image courtesy of: Prof. Nicolas Girard, MD, PhD, Institut Curie, Paris, France.

Presurvey 3: Considering current guidelines and available clinical trial data, how would you manage this patient with recurrent EGFR Ex20ins NSCLC?